The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir

BACKGROUND: Combination therapy with sofosbuvir (SOF) and simeprevir (SIM) is used to treat patients with hepatitis C virus infection. It is currently unknown whether adding ribavirin (RBV) to SOF + SIM, which raises the pill count from two up to eight pills a day, impacts adherence. The aim of this...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clinicoecon Outcomes Res
Autors principals: Walker, David R, Juday, Timothy R, Manthena, Shivaji R, Jing, Yonghua, Sood, Vipan
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2015
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4687623/
https://ncbi.nlm.nih.gov/pubmed/26719716
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S87261
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars